using our proprietary platform technology, gt biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary nk cell engager (trike) platform technology. (nasdaq: gtbp)
Company profile
Ticker
GTBP
Exchange
Website
CEO
Anthony Cataldo
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
OXIS INTERNATIONAL INC
SEC CIK
Corporate docs
IRS number
941620407
GTBP stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
16 Sep 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
424B3
Prospectus supplement
2 Jul 24
EFFECT
Notice of effectiveness
1 Jul 24
S-1/A
IPO registration (amended)
27 Jun 24
8-K
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
27 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
26 Jun 24
S-1
IPO registration
18 Jun 24
DEFA14A
Additional proxy soliciting materials
17 Jun 24
8-K
Departure of Directors or Certain Officers
7 Jun 24
Transcripts
Latest ownership filings
4
ALAN LOUIS URBAN
21 Oct 24
3
ALAN LOUIS URBAN
13 Jun 24
SC 13G/A
BRISTOL INVESTMENT FUND LTD
23 May 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
CYTOVANCE BIOLOGICS INC
19 Sep 23
4
Michael Martin Breen
15 Aug 23
4
Manu Ohri
15 Aug 23
4
CHARLES J CASAMENTO
21 Jun 23
3
CHARLES J CASAMENTO
4 May 23
4
Michael Martin Breen
11 Apr 23
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.25 mm | 9.25 mm | 9.25 mm | 9.25 mm | 9.25 mm | 9.25 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.30 mm | 1.11 mm | 1.18 mm | 975.83 k |
Cash used (since last report) | n/a | n/a | 4.89 mm | 4.16 mm | 4.43 mm | 3.66 mm |
Cash remaining | n/a | n/a | 4.36 mm | 5.09 mm | 4.82 mm | 5.58 mm |
Runway (months of cash) | n/a | n/a | 3.3 | 4.6 | 4.1 | 5.7 |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 15 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 336.27 mm |
Total shares | 4.29 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Cytovance Biologics | 2.76 mm | $860.00 k |
DekaBank Deutsche Girozentrale | 978.36 k | $37.83 mm |
Alpha Capital Anstalt | 265.23 k | $809.00 k |
Bristol Investment Fund | 190.00 k | $0.00 |
BMO Bank of Montreal | 29.87 k | $93.20 mm |
Susquehanna International | 18.98 k | $53.73 mm |
Geode Capital Management | 11.18 k | $31.66 mm |
Vanguard | 10.50 k | $29.73 mm |
WFC Wells Fargo & Company | 10.01 k | $28.34 mm |
BLK BlackRock | 9.77 k | $27.64 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Oct 24 | Urban Alan Louis | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 2.11 | 23,335 | 49.24 k | 23,335 |
11 Aug 23 | Manu Ohri | Common Stock | Other | Acquire J | Yes | No | 0.287 | 200,000 | 57.40 k | 300,000 |
11 Aug 23 | Manu Ohri | Common Stock | Other | Dispose J | No | No | 0.287 | 200,000 | 57.40 k | 0 |
11 Aug 23 | Manu Ohri | Common Stock | Grant | Acquire A | No | No | 0.287 | 200,000 | 57.40 k | 200,000 |
11 Aug 23 | Michael Martin Breen | Common Stock | Grant | Acquire A | No | No | 0.287 | 200,000 | 57.40 k | 856,218 |
16 Jun 23 | Casamento Charles J | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.35 | 500,000 | 175.00 k | 500,000 |
Press releases
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
26 Sep 24
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
24 Sep 24
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
14 Aug 24